FDA approves Teva’s monthly injection of olanzapine for schizophrenia
The most widely used atypical antipsychotic is now available as a once-monthly injection for schizophrenia patients after a US Food…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Big tech- and pharma-backed Iambic Therapeutics aims for $135m IPO
Iambic Therapeutics, a biotech that has won favour not just with investors but has also garnered support from pharma companies,…
-
Change lifestyle before giving children weight loss medication, WHO says
The World Health Organization (WHO) has urged health authorities to first seek lifestyle interventions to treat obesity in children and…
-
CAR-T specialist Caribou culls pipeline and seeks exit deal
Caribou Biosciences, a biotech developing off-the-shelf cell therapies for blood cancers, said it will discontinue its pipeline and lay off…
-
Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
Roche is paying up to $1.27bn to gain the global rights to Alector’s Parkinson’s disease candidate, giving the drugmaker access…
-
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
Having already brought one of the most successful drugs in the world to market, Sanofi and Regeneron are broadening their…
-
Atossa plans shareholder stake in potential PRV proceeds
Atossa Therapeutics has put in place a plan that would give its shareholders a share of any proceeds from the…
-
Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa
Novo has signed a license agreement with Nanexa to use the Swedish biotech’s longer-lasting drug delivery technology, as the company…
-
FDA commissioner nominee affirms MMR vaccine safety despite Trump’s claims
Dr Heidi Overton, Donald Trump’s nominee to lead the US Food and Drug Administration (FDA), has affirmed the safety and…
-
Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare
Eli Lilly has partnered with China-based InnoCare Pharma in a five-drug strong research and license pact. As per the deal,…